HitGen Inc. (SHA:688222)
China · Delayed Price · Currency is CNY 22.72
+0.42 (1.88%)
At close: Aug 22, 2025, 2:57 PM CST
HitGen Revenue
HitGen had revenue of 106.74M CNY in the quarter ending March 31, 2025, a decrease of -0.60%. This brings the company's revenue in the last twelve months to 426.34M, up 4.21% year-over-year. In the year 2024, HitGen had annual revenue of 426.99M with 14.99% growth.
Revenue (ttm)
426.34M
Revenue Growth
+4.21%
P/S Ratio
21.29
Revenue / Employee
882.69K
Employees
483
Market Cap
9.08B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 426.99M | 55.66M | 14.99% |
| Dec 31, 2023 | 371.32M | 41.67M | 12.64% |
| Dec 31, 2022 | 329.65M | 18.59M | 5.98% |
| Dec 31, 2021 | 311.06M | 67.46M | 27.69% |
| Dec 31, 2020 | 243.60M | -20.60M | -7.80% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jiangsu Hengrui Medicine | 30.15B |
| Shenzhen Mindray Bio-Medical Electronics | 35.59B |
| WuXi AppTec | 41.90B |
| Sichuan Biokin Pharmaceutical | 441.19M |
| Zhangzhou Pientzehuang Pharmaceutical., | 10.52B |
| Aier Eye Hospital Group | 21.81B |
| Shanghai United Imaging Healthcare | 10.43B |
| Yunnan Baiyao Group Co.,Ltd | 40.10B |